NCT01818687终止3 期
A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Chronic Kidney Disease Stages 3b to 5 and With Hyperphosphataemia Not on Dialysis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Percentage of subjects who, due to hyperphosphataemia, require rescue treatment and/or discontinuation of therapy with colestilan.
研究概览
简要总结
The objective of this study is to assess the safety and tolerability of colestilan (MCI-196) in paediatric subjects (aged 2 years to <18 years) with CKD stages 3b to 5, diagnosed with hyperphosphataemia, who are not on dialysis.
详细描述
This study has been terminated because of insufficient patient recruitment. There were no safety concerns.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children aged 2 years to <18 years with CKD stages 3b to 5, not on dialysis (stage 3b is defined as a glomerular filtration rate below 45 mL/min/1.73 m²).
- •The subject has a documented diagnosis of hyperphosphataemia, as demonstrated by serum phosphorus (P) levels above the age-related upper limit of normal (ULN) (Kidney Disease Outcomes Quality Initiative [KDOQI] Clinical Practice Guidelines for Nutrition in Children with CKD updated 2008).
- •The subject is on a stable P diet at baseline (as judged by the Investigator).
- •Inclusion criteria for subjects not currently treated with phosphate binders:
- •The subject, with serum P not controlled despite being on an appropriate P diet, must demonstrate serum P levels >1.5 standard deviation (SD) above the KDOQI 2008 age-related mean value at any time during the screening period. Such subjects do not require wash-out and should proceed to baseline for the next visit if additional screening visits are not required.
- •Baseline inclusion criteria for subjects treated with phosphate binders:
- •The subject must enter the wash-out period, during which he/she must demonstrate serum P levels >1.5 SD above the KDOQI 2008 age-related mean value at any time during the wash-out period (after stopping phosphate binders), and;
- •The subject must demonstrate an increase in serum P levels by at least 10% above the pre wash-out level (after stopping phosphate binders).
- •Note: should a subject fail to meet any of the above criteria, the subject is permitted to be re-screened once after an interval of at least three months.
排除标准
- •The subject has been diagnosed with hypocholesterolaemia (i.e., cholesterol levels below age-related normal ranges, per local practices)
- •The subject has current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, make the subject unsuitable for inclusion in the study (e.g., the subject currently has or has had a history of seizure disorders, dysphagia, swallowing disorders, predisposition to or current bowel obstruction, ileus or gastrointestinal [GI] disorders such as chronic or severe constipation [as judged by the Investigator], intestinal stenosis, intestinal diverticulum, sigmoid colitis, GI ulcers, current or a history of GI bleeding, or major GI tract surgery)
- •The subject cannot stop treatment (prescription or over the-counter) of any of the following orally taken medications during the wash-out period: any product containing calcium (Ca), magnesium (Mg), aluminium compounds, sevelamer, lanthanum, ketosteril
- •The subject is receiving immunosuppressant treatment for any medical condition at the baseline visit or is expected to receive such treatment during the course of the study
- •The subject is considered as unstable on his/her current treatment for CKD within one month prior to screening (e.g., subjects starting treatment with vitamin D or its analogues, or other agents/procedures that may influence bone mineral metabolism [i.e, serum P and Ca levels]
- •Exclusion criteria for subjects treated with phosphate binders:
- •The subject was treated with a combination of two or more phosphate binders within one month prior to screening
研究组 & 干预措施
MCI-196 (Flexible dose)
Experimental
MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
干预措施: colestilan (Drug)
结局指标
主要结局
Percentage of subjects who, due to hyperphosphataemia, require rescue treatment and/or discontinuation of therapy with colestilan.
时间窗: 17 weeks
次要结局
- Laboratory safety assessments(17 weeks)
- Incidence of TEAEs of hypercalcaemia and hypocalcaemia(17 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab PegolCrohn's DiseaseNCT01190410UCB Pharma16
已完成
1 期
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid ArthritisRheumatoid ArthritisNCT04740814UCB Biopharma SRL33
已完成
3 期
Study of PlasmaCap IG in Adults and Children With PIDDPrimary Immune Deficiency Diseases (PIDD)NCT03238079Evolve Biologics63
已完成
1 期
A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With EpilepsyEpilepsyNCT04857307UCB Biopharma SRL14
已完成
1 期
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCIAcute Spinal Cord InjuryNCT00406016Novartis52